IP Library Granted Patent US 11,161,890
Granted Patent B2
US 11,161,890 · App. 16/114,870 · Granted Nov 2, 2021

IL-15-based fusions to IL-7 and IL-21

Inventor: Hing C. Wong (Weston, FL)
Assignee: Altor Bioscience LLC.
C07K14/5443A21D8/047A61K38/2086A61P37/04C07K14/54C07K14/5418C07K14/7155C12N15/81A61K38/00C07K2319/00C07K2319/02C07K2319/30C12Y302/01002C12Y302/0106C12Y302/01033
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,161,890
App. No.
16/114,870
Granted
Nov 2, 2021
Kind
B2
Abstract

The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-7 or IL-21.

Claims (6)

1. An isolated soluble fusion protein complex comprising at least two soluble proteins, wherein: a first soluble protein comprises a polypeptide according to SEQ ID NO:4, and a second soluble protein comprises a polypeptide according to SEQ ID NO:2, wherein the first and second soluble proteins are covalently linked by a disulfide bond to form the soluble fusion protein complex.

2. The soluble fusion protein complex of claim 1 , wherein the first soluble protein consists of SEQ ID NO:4 and the second soluble protein consists of SEQ ID NO:2.

3. The soluble fusion protein complex of claim 1 , wherein the first and/or second soluble protein are associated with a biologically active moiety.

4. The soluble fusion protein complex of claim 3 , wherein the biologically active moiety comprises cytokines, antibodies, T cell receptors, receptor binding molecules, receptor domains, immune checkpoint agonists, immune checkpoint antagonists, chemokines, growth factors, toxins, cytotoxic agents, or combinations thereof.

5. The soluble fusion protein complex of claim 4 , wherein the biologically active moiety comprises one or more cytokines.

6. The soluble fusion protein complex of claim 1 , wherein the first soluble protein contains an Fc domain and is covalently linked to the second soluble protein by a disulfide bond linking the Fc domain of the first soluble protein to the Fc domain of the second soluble protein.

Assignments (2)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
EMPLOYMENT AGREEMENT Recorded Apr 13, 2021
From: WONG, HING C.
To: ALTOR BIOSCIENCE, LLC
Reel/Frame 056004/0544 →
Continuity (2)
Provisional Application 62551218 · Aug 28, 2017
Related Publication 20190300591A1 · Oct 3, 2019
Cited By (3)
US 12,410,224 US 12,590,129 US 12,630,595